Buradasınız

Anasayfa » Content

PARAOKSONAZ

Journal Name:

  • Cerrahpaşa Tıp Dergisi

Publication Year:

  • 2004

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Paraoxonase (PON1) is a calcium-dependent esterase that is a component of plasma high density lipoprotein (HDL), and hydrolazes organophosphates (e.g. paraoxon, diazooxon), aromatic carboxylicacid esters and nerve gases. Paraoxonase protects low density lipprotein (LDL) and HDL from oxidation induced by either copper (Cu) ion, or free radicals. This protection is probably related to PON's ability to hydrolyze some oxidized phospholipids and/or cholestryl linoleate hydoperoxidases which are present in Ox-LDL. PON1's free sulpfhydryl group of cystein-284 is required for PON1's ability to protect LDL against oxidation.
Bookmark/Search this post with
Abstract (Original Language): 
İnsan serum Paraoksonaz (PON1) enzimi; HDL üzerinde lokolize, kalsiyum (Ca) bağımlı bir ester hidrolazdır ve organofosfatları (para-okson, diazookson gibi) sinir ajanlarını ve aro-matik karboksilik asit esterlerini hidroliz eder. Ayrıca; LDL ve HDL'yi, Cu iyonunun ve ser-best radikallerin indüklediği oksidasyondan koruyarak antioksidan etki gösterir. Paraokso-naz enzimi, okside LDL’de bulunan kolesterol linolat hidroperoksitleri ve/veya okside fosfoli-pidleri hidroliz ederek bu koruyucu etkisini gösterebilir. Paraoksonaz enzimi sistein 284 pozisyonunda serbest sülfidril grubu içerir ve bu yapı oksidasyona karşı LDL' yi korumada önem taşımaktadır.
FULL TEXT (PDF): 
PDF icon arastirmax-paraoksonaz.pdf
  • 2
78-82
  • Turkish

REFERENCES

References: 

1. Abbot CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentrations and phenotype distribution in diabetes mellitus its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Bio. 1995; 15: 1812-18.
2. Heijmans BT, Westendorp RGJ, Lagaay AM, Knook DL, Kluft C, Slagboom PE. Common paraoxonase gene variants, mortality risk and fatal cardiovascular events in elderly subjects. Atherosclerosis, 2000; 149: 91-7.
3. Kelso GJ, Stuart WD, Richter RJ, Furlong CE, Jordon-Starck TJ, Harmony JAK. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry 1994; 33: 832-39.
4. Hasselwander O, McMaster D, Fogarty AD, Maxwell AP, Nicholls DP, Young JS. Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure. Clin Chem 1998; 44: 179-82.
5. Mackness B, Hunt R, Durrington PN, Mackness MI. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vasc Biol.1997; 17: 1233-38.
6. McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem, 1986; 32: 671-3.
7. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, Billicke S, Draganov D, Rosenblat M. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions. Circulation 2000; 101: 2510-17.
8. Garin MCB, Abbot C, Messmer S, Mackness M, Durrington P, Pometta D, James RW. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J 1994; 304: 549-54.
9. La Du BN, Aviram M, Billecke S, Navab M. On the physical role(s) of the paraoxonases. Chem -Biol Inter 1999; 119-120: 379-88.
10. Mackness B, Durrington PN, Mackness MI. Human serum Paraoxonase. Gen Pharm 1998; 3: 329-36.
11. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001; 21: 473-80.
12. Rye KA, Clay MA, Barter PJ. Remodelling of high-density lipoproteins by plasma factors. Atherosclerosis 1999; 145: 227-238.
13. Heinecke JW. Eosinophil-dependent bromination in the pathogenesis of asthma. J Clin Invest, 2000; 105: 1331-2.
14. Aviram M, Rosenblat M, Scott B, Erogul J, Sorenson R, Bisgaier CI, Newton RS, La Du B. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Rad Biol & Med 1999; 26: 892-904.
15. Shoji T, Nishizawa Y, Fukumato M, Shimamura K, Kimura J, Kanda H, Emoto M, Kawagishi T, Morri H. Inverse relationship between circulating oxidized low density lipoprotein (OxLDL) and anti-oxidized LDL antibody levels in healthy subjects. Atherosclerosis, 2000; 148: 171-7.
16. Heijmans BT, Westendorp RGJ, Lagaay AM, Knook DL, Kluft C, Slagboom PE. Common paraoxonase gene variants, mortality risk and fatal cardiovascular events in elderly subjects. Atherosclerosis, 2000; 149: 91-7.
17. Kwiterovich PO. The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol. 1998; 82: 13Q-21Q.
18. Lee J, Prohaska JR, Thiele DJ. Essential role for mammalian copper transporter Ctr 1 in copper homeostasiss and embryonic development. Proc Natl Acad Sci, 2001; 98: 6842-47.
19. Mackness MI, Arool S, Mackness B, Durrington PN. Alloenzymes of paraoxonase and effectiveness of high
CERRAHPAŞA TIP DERGİSİ Cilt (Sayı) 35 (2)
82
density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. The Lancet 1997; 349: 851-2.
20. Mackness MI, Arrol S, Abbott C, Durrington PN. The role of high-density lipoprotein and lipid soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 1993; 294: 829-34.
21. Laıtınen LA, Laıtınen A, Haahtela T. Airway mucosal inflammation even in patients with newly diagnosed asthma. Am Rev Respir Dıs. 1993; 147; 697-704.
22. Mackness MI, Mackness B, Arrol S, Wood G, Bhatnagar D, Durrington PN. Presence of paraoxonase in human interstitial fluid. FEBS Letters, 1997; 416: 377-80.
23. Alı AB, Zhang Q, Lım YK, Fang D, Retnam L, Lım SK. Expression of major HDL-associated antioxidant PON-1 is gender and regulated during inflammation. Free Rad Bio & Med 2003; 34: 824-9.
24. Griffith MK, Virella GT, Stevenson HC, Lopes-Virella MF. Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J Exp Med 1988; 168: 1041-59.
25. Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein- associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 2000; 275: 4435-42.
26. Aviram M. Does paraoxonase play a role in susceptibility to cardiovascular disease? Mol Med Tod 1999; 5: 381-6.
27. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La dU BN. Human serum paraoxonase/arylesterase's retained hyrophobic N-terminal leader sequence associates with HDLs by binding phospholipids. Arterioscler Thromb Vasc Biol. 1999; 19: 2214-25.
28. Sönmez H. Lipid metabolizmasının ana hatları, primer ve sekonder hiperlipidemiler. Türkiye Klinikleri, 2000; 13: 1-8.
29. Cathcart MK, McNally AK, Chisolm GM. Lipoxygenase-mediated transformation of human low density lipoprotein to oxidized and cytotoxic complex. J Lipid Res 1991; 32: 63-70.
30. Maron DJ, Ridker PM, Pearson TA, Grundy SM. Dyslipidemia, other risk factors, and the prevention of coronary heart disease. Ch 38. In: Fuster V, Alexander RW, O'Rourke R. Hurst's The Heart 10th edn. McGraw-Hill Companies. USA 2001; 1131-60.
31. Sanders SP. Asthma, viruses, and nitric oxide. Proc Soc Exp Biol. Med 1999; 220: 123-32.
32. Cao H, Girard-Globa A, Berthezene F, Moulin P. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q → R genetic polymorphism. J Lipid Res 1999; 40: 133-9.
33. James RW, Garin MCB, Calabresi L, Miccoli R, Eckardstein AV, Tilly-Kiesi M, Taskinen MR, Assmann G, Franceschini G. Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states. Atherosclerosis, 1998; 139: 77-82.
34. James RW, Leviev I, Righetti A. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 2000; 101: 2215-57.
35. Aviram M, Rosenblat M, Bisgair CL. Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581-90.
36. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, Billicke S, Draganov D, Rosenblat M. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions. Circulation 2000; 101: 2510-17.
37. Nelson DL, Cox MM. Lipid Biosynthesis. ch 21. In: Lehninger principles of Biochemistry 3rd edn. Worth Publishers. New York 2000; 770-817.
38. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997; 272: 20963-66.
39. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis, 1993; 104: 129-35.
40. Watson AD, Navab SY, Hama A. Effect of platelet-activating factor-acetyhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 1995; 95: 774-82.
41. Biasioli S, Schiavon R, Petrosino L, De Fanti E, Cavalcanti G, Battaglia P, Fasolin A. Paraoxonase activity and paraoxonase 1 gene polymorphism in patients with uremia. ASAIO J. 2003; 49: 295-9.
42. Seres I, Paragh G, Deschene E, Fulop T Jr, Khalil A. Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp Gerontol, 2004; 39: 59-66

Thank you for copying data from http://www.arastirmax.com